18 October 2021
EMA/CAT/515396/2021
Human Medicines Division

Committee for Advanced Therapies (CAT)

Minutes of the meeting on 08-10 September 2021

Chair: Martina Schuessler-Lenz; Vice-Chair: Ilona Reischl

Disclaimers

Some of the information contained in these minutes are considered commercially confidential or sensitive and therefore not disclosed. Regarding intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, these minutes are a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

Table of contents

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

The Chairperson opened the meeting by welcoming all participants. Due to the current coronavirus (COVID-19) outbreak, and the associated EMA Business Continuity Plan (BCP), the meeting was held remotely.

In accordance with the Agency's policy on handling of declarations of interests of scientific Committees' members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and on the topics in the agenda of the meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants for agenda topics was identified. Participants were asked to declare any changes, omissions or errors to their declared interests concerning the matters for discussion. No new or additional competing interests were declared. Restrictions applicable to this meeting are captured in the List of participants included in the minutes.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The Chair welcomed the new member(s) and alternate(s) and thanked the departing members/alternates for their contributions to the Committee.

1.2. Adoption of agenda

The CAT agenda for 08-10 September 2021 meeting was adopted.

1.3. Adoption of the minutes

The CAT minutes for 14-17 July 2021 meeting were adopted.

The CAT minutes of the 11-13 August 2021 written procedure were adopted.

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

No items

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

2.4.1. Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095

Accelerated assessment

Janssen-Cilag International NV; treatment of multiple myeloma

Scope: Day 120 list of questions

Action: for adoption

The Rapporteurs presented the outcome of the initial assessment.

In view of the timing to respond to the major objection, the applicant requested to revert to normal assessment timeframe.

CAT adopted the list of questions and the response timetable.

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

2.6.1. Autologous glioma tumor cells, inactivated / autologous glioma tumor cell lysates, inactivated / allogeneic glioma tumor cells, inactivated / allogeneic glioma tumor cell lysates, inactivated - Orphan - EMEA/H/C/003693

Epitopoietic Research Corporation-Belgium (E.R.C.); treatment of glioma

Scope: MAA's request (dated 27.08.2021) for a clock-stop extension

Action: for information

List of Questions adopted on 22.01.2021.

Note: the revised timetable was adopted via written procedure.

2.7. New applications

2.8. Withdrawal of initial marketing authorisation application

No items

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication

procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - darvadstrocel - Orphan - EMEA/H/C/004258/II/0027

Takeda Pharma A/S

CAT Rapporteur: Lisbeth Barkholt

Scope: Quality. Opinion

Action: for adoption

The opinion was adopted.

2.11.2. Imlygic - talimogene laherparepvec - EMEA/H/C/002771/II/0044

Amgen Europe B.V.

CAT Rapporteur: Heli Suila, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: PhV. Opinion

Submission of the final report from study 20180099 listed as a category 3 study in the risk management plan (RMP). This is a cross-sectional survey to evaluate physician knowledge of safety messages included in the physician education booklet (PEB) for Imlygic.

Action: for adoption

Request for Supplementary Information adopted on 16.07.2021, 12.05.2021.

The opinion was adopted.

2.11.3. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102/II/0008/G

Kite Pharma EU B.V.

CAT Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst

Scope: Clinical. Request for supplementary information

Group of variations including an extension of indication to include treatment of adult patients with relapsed or refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) for Tecartus and a type IB variation to change the Drug Product Dose specification for the new indication. As a consequence, sections 2.2, 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet and labelling are updated in accordance. Version 1.1 of the risk management plan (RMP) has also been submitted. Furthermore, the product information (PI) is brought in line with the latest quality review document (QRD) template.

Action: for adoption

The request for supplementary information was adopted.

2.11.4. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0040

Kite Pharma EU B.V.

CAT Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Anette Kirstine Stark

Scope: PhV. Request for supplementary information

Submission of the final study report for the non-interventional study KT-EU-471-0116

(quantitative testing of healthcare provider knowledge about Yescarta (axicabtagene ciloleucel) risk minimisation measures) in fulfilment of an additional pharmacovigilance activity (Category 3) listed in the EU risk management plan (RMP) for Yescarta.

Action: for adoption

This variation is in the remit of PRAC. It relates to the monitoring of the effectiveness of the risk minimisation measures (RMM). This is a requirement in the pharmacovigilance legislation (required whenever education materials are felt necessary).

CAT questions the value of such a study. CAT considered that more reflection should be given to the type of study to evaluate the effectiveness of the RMM at the time of the MA, in order to get relevant data without increasing the administrative burden in the treatment centers.

CAT adopted the request for supplementary information as proposed by PRAC.

2.11.5. Zynteglo - betibeglogene autotemcel - Orphan - EMEA/H/C/003691/II/0025

bluebird bio (Netherlands) B.V

CAT Rapporteur: Carla Herberts

Scope: Quality. Opinion

Action: for adoption

Request for Supplementary Information adopted on 18.06.2021.

The opinion was adopted.

2.11.6. Tecartus; Yescarta - axicabtagene ciloleucel; autologous anti-CD19-transduced CD3+ cells - Orphan - EMEA/H/C/WS2071

Kite Pharma EU B.V.

CAT Rapporteur: Jan Mueller-Berghaus

Scope: Quality. Request for supplementary information

Opinion

Action: for adoption

Request for Supplementary Information adopted on 16.07.2021.

The request for supplementary information was adopted.

2.12. Extension applications

No items

2.13. Other Post-Authorisation Activities

2.13.1. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/ANX/003

Orchard Therapeutics (Netherlands) BV

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Progress report
Measures proposed to reduce the overall time from patient screening to treatment.

Action: for adoption

The report was adopted.

2.13.2. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/REC/004

Orchard Therapeutics (Netherlands) BV

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Quality. Progress report

Action: for adoption

The report was adopted.

2.13.3. Libmeldy - atidarsagene autotemcel - Orphan - EMEA/H/C/005321/REC/005

Orchard Therapeutics (Netherlands) BV

Rapporteur: Carla Herberts, CHMP Coordinator: Johann Lodewijk Hillege

Scope: Quality

Action: for adoption

The report was adopted.

2.13.4. Tecartus - autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured - Orphan - EMEA/H/C/005102/R/0010

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Rune Kjeken, PRAC Rapporteur: Menno van der Elst

Scope: 1-year Renewal of Marketing Authorisation. Opinion

Action: for adoption

The renewal opinion was adopted.

2.13.5. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/REC/011

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

The report was adopted.

2.13.6. Yescarta - axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/REC/012

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

The report was adopted.

2.13.7. Tecartus - autologous anti-CD19-transduced CD3+ cells - Orphan - EMEA/H/C/005102/REC/008

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

The report was adopted

2.13.8. Skysona – Elivaldogene autotemcel - Orphan – EMEA/H/C/003690

bluebird bio (Netherlands) B.V.; treatment of early cerebral adrenoleukodystrophy

Rapporteur: Lisbeth Barkholt, Co-rapporteur: Anne Pastoft

Scope: New safety findings

Action: for information

The Rapporteur provided information on the case of myelodysplastic syndrome (MDS). A variation will be submitted to update sections 4.4 (to amend the statement on the risk of insertional mutagenesis) and 4.8 of the SmPC.

CAT noted that the product is at present not yet marketed in the EU and that the clinical trial (study 104) is currently put on clinical hold (US trial). CAT agreed that no immediate regulatory action is required

2.13.9. Luxturna – voretigene neparvovec – EMEA/H/C/004451

Novartis Europharm Limited; treatment of patients with vision loss due to Leber congenital amaurosis or retinitis pigmentosa inherited retinal dystrophy

Rapporteur: Sol Ruiz, PRAC Rapporteur : Brigitte Keller Stanislawski

Scope: New safety finding (Progressive chorioretinal atrophy). Feedback from PRAC discussion

Action: for information

The PRAC Rapporteur informed the CAT of the discussion that took place in PRAC on the signal of progressive chorioretinal atrophy (without impact on vision) in patients treated with Luxturna. 11 cumulative events have been reported by the MAH; reference is made to the article published by Gange et all (2021)[1]. A short discussion took place on the possible root cause. CAT agreed with the approach agreed by PRAC.

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

[1] Perifoveal Chorioretinal Atrophy after Subretinal Voretigene Neparvovec-rzyl for RPE65-Mediated Leber Congenital Amaurosis William S Gange, Robert A Sisk, Cagri G Besirli, Thomas C Lee, Margaret Havunjian, Hillary Schwartz, Mark Borchert, Jesse D Sengillo, Carlos Mendoza, Audina M Berrocal, Aaron Nagiel. Ophthalmol Retina . 2021 Apr 8;S2468-6530(21)00106-8. doi: 10.1016/j.oret.2021.03.016.

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

No items

4. Scientific Recommendation on Classification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

4.1. New requests – Appointment of CAT Coordinator

4.1.1. Autologous red blood cells chemically coupled with 12 antigenic peptides

Intended for the treatment of multiple sclerosis

Scope: appointment of CAT Coordinator and adoption of timetable

Action: for adoption

The CAT coordinator was appointed.

4.2. Day 30 ATMP scientific recommendation

4.2.1. Point-of-care skin cell isolation kit

Intended for skin regeneration after burns, skin trauma, invasive surgery

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.2.2. Optimised DNA encoding the sequence of interest COL7A1

Intended for the treatment of dystrophic epidermolysis bullosa (DEB)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.2.3. Adipose derived Mesenchymal Stem/Stromal Cells

Intended for the treatment of amyotropthic lateral sclerosis

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.2.4. Recombinant adeno-associated virus serotype HSC 15 (rAAVHSC15) expressing human iduronate-2-sulfatase (hIDS)

Intended for the treatment of mucopolysaccharidosis type II (known as Hunter syndrome)

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.3. Day 60 revised scientific recommendation (following list of questions)

4.3.1. Extracellular matrix and non-viable osteogenic cells derived from human adipose-derived stem cells, associated with hydroxyapatite/beta-tricalcium phosphate (HA/βTCP) particles

Intended to stimulate bone regeneration in pathological hypoxic and/or necrotic bone conditions

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report that was updated to include the additional information from the applicant. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.3.2. Isolated CD31+ cells

Intended for the treatment of erectile dysfunction

Scope: ATMP scientific recommendation

Action: for adoption

CAT discussed the ATMP classification report that was updated to include the additional information from the applicant. CAT secretariat to send the draft scientific recommendation to the European Commission for comments by 24 September 2021.

4.4. Finalisation of procedure

No items

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	30.08-02.09.2021
- Appointment of CAT Peer Reviewers:	08-10.09.2021
- SAWP first reports:	20.09.2021
- CAT Peer Reviewer comments:	24.09.2021
- Discussion at SAWP:	27-30.09.2021
- Discussion at CAT and feedback to SAWP:	08.10.2021

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:s

- Start of procedure at SAWP:	27-30.09.2021
- Appointment of CAT Peer Reviewers:	06-08.10.2021
- SAWP first reports:	18.10.2021
- CAT Peer Reviewer comments:	22.10.2021
- Discussion at SAWP:	25-28.10.2021
- Discussion at CAT and feedback to SAWP:	05.11.2021

5.2. Procedures discussed at SAWP – 1st report and D40 JRs, LoOIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:

Procedure start:	02.09.2021
SAWP recommendation:	30.09.2021
CAT recommendation:	08.10.2021
CHMP adoption of report and final recommendation:	14.10.2021

6.3.2. Month 1 – Discussion of eligibility

No items

6.3.3. Month 2 – Recommendation of eligibility

No items

6.3.4. Ongoing support

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

Action: for information

The Chair welcomed Tomáš Boráň, as new member for Czech Republic, Petr Soukup, as the new alternate for Czech Republic and Suzana Vidic, as the new alternate member for Slovenia

The Chair thanked Ivana Haunerova for her contribution as a member for Czech Republic, and Nevenka Tršinar Brodt for his contribution as alternate members for Slovenia.

7.1.2. Vote by proxy

Action: for information

None.

7.1.3. Joint CAT-CHMP Strategic Review & Learning (virtual) meeting (SRLM) under the Slovenian presidency, 21 October 2021, virtual

CAT: Metoda Lipnik-Štangelj, Martina Schuessler-Lenz

Scope: Practical information and agenda content

Action: for discussion

The draft agenda was presented. The SRLM will be held virtually (via Webex).

The agenda of the joint CAT-CHMP session (morning session) was agreed.

For the afternoon session, it was proposed to broaden the first session to all AAV safety signals and allow more time to report back from the FDA Advisory Committee meeting on AAV gene therapy safety (see agenda point 7.5.4). With this amendment, the agenda of the afternoon CAT session was also agreed.

7.1.4. Pilot – Relaunch of face to face Scientific Committee meetings

Action: for discussion

The CAT was informed about the expected set-up for returning to Committee face-to-face meetings.

7.1.5. CAT rules of procedure - revision

Action: For adoption

To reflect the meeting approach for the pilot for the relaunch of face to face committee meetings, the CAT Rules of Procedure required revision. The opportunity was taken to introduce some other changes to facilitate the functioning of the committees and for consistency reasons.

The revised CAT rules of procedure were adopted. Coordination with EMA Scientific Committees

7.1.6. Scientific Coordination Board (SciCoBo) – meeting of 03 September 2021

CAT: Martina Schuessler-Lenz

Scope: feedback on the discussions in the SciCoBo meeting

Action: for discussion

The agenda of the last SciCoBo meeting was presented. Evaluation and grading of neurotoxicities for CAR-T cells ATMPs – a proposal for using ICANS

Scope: ICANS in CAR-T post-autorisation reports

Action: for agreement

Note: During its July meeting, CAT agreed in principle to use ICANS for the reporting of neurotoxicity for CAR-Ts. The proposal was also discussed in PRAC. Formal endorsement by CAT and PRAC will take place in September.

Further to the endorsing by PRAC, CAT also agreed with the implementation of the use of ICANS. EMA will inform the applicants and MAHs and include this position in ATMP safety guidance or general pharmacovigilance guidelines.

CAT asked if the scope should not be extended to other products (e.g. other immune effector cells, bispecific antibodies). It was agreed to start with CAR-Ts and consider expansion at a later stage.

7.2. Coordination with EMA Working Parties/Working Groups/Drafting Groups

7.2.1. Final guideline on registry-based studies

Action: for information

CAT noted the presentation on the final guideline on registry-based studies that was updated after the public consultation.

7.2.2. Working Party with Patients' and Consumers' Organisations (PCWP) and Working Party with Healthcare Professionals' Organisations (HCPWP)

Scope: draft agenda of the PCWP/HCPWP joint meeting on the 21-22 September 2021

Action: for information

The information was noted.

7.3. Cooperation with the EU regulatory network

7.3.1. Revision of the EU legislation on blood, tissues and cells (BTC)

CAT: Martina Schüssler-Lenz

Action: for discussion

Scope: exchange with the European Commission representative

The European Commission representative provided state of play or the revision of the BTC legislation. Some examples of innovation in the BTC sector were presented (to clarify that not all novel BTC are borderlines with ATMPs). Key legal elements on innovation that will be included in the BTC revision are: filling legal gaps, setting up an advisory committee (on when/what BTC requirements will apply) and developing a 'preparation process authorisation' mechanism for BTC. During the open consultation, a lack of clarity at borderlines with other frameworks was identified, as well as the interplay when BTC as starting material for other regulated products (e.g. medicines, ATMPs). The Commission's view on how to set up a joint borderline clarification mechanism and on authorisation of novel BTC were subsequently presented. The Commission representative informed CAT that the Commission is now drafting the impact assessment and legal proposal.

CAT noted the statement from the Commission that there are no plans to revise the legal definitions on what is "industrial manufacturing, substantial manipulation and non-homologous use" within the BTC revision, but that the intention was to provide more clarification. CAT had reservations on the need to further clarify these definitions. CAT also pointed out that in the proposal for 'preparation process authorisation', the concept of efficacy demonstration was missing (focus on safety and quality and that this was a concern in the context of public health protection and preventing the use of unproven cell-based medicines. CAT also questioned the role of the advisory committee in classification discussions. It was questioned if the unclarity flagged in the public consultation was really on the borderline between ATMPs and BTC (to CAT's understanding, the main issues were with faecal microbiota and breast milk).

On the question on further inputs from and interactions with CAT, the Commission representative indicate that CAT will be further consulted on some additional borderline classifications.

7.4. Cooperation with international regulators

7.4.1. WHO consultation on cell and gene therapy products

CAT: Ilona Reischl

Action: for information

Note: CAT members are asked to provide comments to Ilona Reischl, cc. CAT secretariat by Tuesday 7 September

The comments provided by CAT members were presented and discussed. The compiled comments will now be sent to WHO as the CAT contribution.

7.4.2. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Martina Schuessler-Lenz

Scope: Feedback from the teleconference that took place on 22 July 2021

Action: for information

A short feedback was provided from the discussions at the ATMP cluster teleconference.

7.4.3. International Pharmaceutical Regulators Programme (IPRP) – Gene therapy and cell therapy working group

CAT: Pille Säälik

Scope: Agenda of the international teleconference that took place on 22 July 2021

Action: for Information

A short feedback was provided from the discussions at the IPPR gene and cell therapy working group teleconference.

7.4.4. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Martina Schuessler-Lenz

Scope: Topic for the agenda of the teleconference that will take place on 16 September 2021 (TBC)

Action: for discussion

CAT noted the postponement of the next ATMP cluster teleconference to 14 October 2021.

7.4.5. FDA Advisory committee meeting on AAV gene therapy safety

CAT: Lisbeth Barkholt

Scope: Feedback from the Advisory committee meeting that took place on 2 – 3 September 2021

Action: for information

This feedback will be provided at the upcoming SRLM (see 7.1.3).

7.5. CAT work plan

7.5.1. Real World Data (RWD) in regulatory decision making of ATMPs

CAT: Martina Schuessler-Lenz

Scope: Feedback from the second meeting

Action: for information

EMA and the CAT chair provided feedback from the discussion in the meeting of the CAT subgroup on RWD. EMA can support CAT with real world evidence (RWE) information either based on EMA studies on in-house accessible databases, via studies procured through the EMA framework contracts and in the future using DARWIN. Such RWE support can be provided during a procedure or independent from a specific procedure.

The proposal to conduct a case study on spinal muscular dystrophy was agreed by CAT. The research questions will need to be finalised: proposal is to collect data on natural history, clinical management and availability of EU disease registries. Kieran Breen agreed to act as the Committee lead for this activity.

7.6. Planning and reporting

7.6.1. Planning estimates of forthcoming ATMP MAAs

Scope: Q3/2021 update of the business pipeline report for the human scientific committees

Action: for information

The information was noted.

7.7. Others

7.7.1. CAT stakeholder meeting on 26 October 2021

CAT: Martina Schuessler-Lenz

Scope: revision of agenda topics

Action: for discussion

The draft agenda for the CAT stakeholder meeting was discussed. The first part of the meeting will be completed based on suggestions by the stakeholders (deadline for their proposals is 30 September 2021). The second part will be on Real World Data (RWD) in regulatory decision making of ATMPs.

CAT identified a couple of topics that would be worth discussing with the stakeholders: PRIME for ATMPs, linked to the maturity of the dossiers, especially the quality module; international collaboration and the use of parallel SA with FDA; Comprehensiveness criteria (to be addressed in the MAA).

The agenda will be finalised and adopted at the October CAT meeting.

7.7.2. Lifecycle Regulations Submissions Raw Data (LRSR)

Action: for information

Topic postponed to the October CAT meeting.

7.7.3. IRIS training for COMP/CAT/BWP

Action: for information

The information was noted.

7.7.4. EMA new emergency notification system

Action: for information

The information on the new emergency notification system was noted.

8. Any other business

No items

Date of next CAT meeting:

06-08/10/2021

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

Abbreviations / Acronyms

AAV: Adeno-Associated Virus

AR: Assessment Report

ATMP: Advanced Therapy Medicinal Product

BWP: Biologics Working Party

CAT: Committee for Advanced Therapies

CHMP: Committee for Medicinal Product for Human Use

COMP: Committee for Orphan Medicinal Products

CTFG: Clinical Trial Facilitation Group

DG: Drafting Group

EC: European Commission

EU NTC: European Union Network Training Centre

ERA: Environmental Risk Assessment

FDA: Food and Drug Administration

FL: Final Letter

GCG: Guideline Consistency Group

GCP: Good Clinical Practice

GLP: Good Laboratory Practice

GMO: Genetically-modified organism

GMP: Good Manufacturing Practice

GTMP: Gene Therapy Medicinal Product

HTA: Health Technology Assessment Bodies

HSPC: Hematopoietic Stem and Progenitor Cells

ITF: Innovative Task Force

JR: Joint Report

LoOI: List of outstanding issues

LoQ: List of questions

MA: Marketing Authorisation

MAA: Marketing Authorisation Application

MAH: Marketing Authorisation Holder

MNAT: Multinational assessment team

MSC: Mesenchymal stem cells

PDCO: Paediatric Committee

PMDA: Pharmaceuticals and Medical Devices Agency (Japan)

PIP: Paediatric Investigation Plan

PL: Package leaflet

PRAC: Pharmacovigilance and Risk Assessment Committee #

PRIME: Priority Medicines

QRD: Quality review of documents

RMP: Risk Management Plan

RP: Reflection paper

RSI: Request for supplementary information

SAs: Scientific Advices

SAG-O: Scientific Advisory Group Oncology

SAWP: Scientific Advice Working Party

SR: Summary Report

SWP: Safety Working Party

SME: Small and medium size enterprises

SmPC: Summary of Products Characteristics

TT: Timetable

Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists any ATMP related inspection requests (section 2.9) and Post-authorisation activities (section 2.10).

New applications (sections 2.1. to 2.12.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found here.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.3) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures**). Section 2.7 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.6.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

Withdrawal of applications (section 2.7.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

New applications (section 2.9.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

GMP and GCP Inspections Issues (section 2.10.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.12.)

This section lists type II variations, extension application according to Annex I of Reg. 1234/2008, re-examination procedures for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP and other issues concerning authorised medicines that are not covered elsewhere in the agenda such as annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found here.

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found here.

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found here.

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found here.

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/